Medicine for treating depression

Abstract

The invention discloses a medicine for treating depression. The medicine is prepared from the following medicinal raw materials in parts by mass: 5-20 parts of fructus forsythiae, 10-50 parts of ramulus mori, 10-60 parts of cortex magnolia officinalis, 5-30 parts of poria, 10-50 parts of radix clematidis, 10-50 parts of radix puerariae, 10-50 parts of radix angelicae sinensis, 5-30 parts of rhizoma acori graminei, 5-30 parts of radix paeoniae alba and 5-30 parts of radix cyathulae. The medicine provided by the invention, starting from concept of wholism and on the basis of dialectical therapy, is concrete and lasting in curative effect, and is high in safety and high in medication compliance on patients; specifically, for light and moderate patients, lifestyle is adjusted; the medicine, on the basis of traditional Chinese medicine treatment, is safe, effective and economic; and treatment demands of patients with the depression can be satisfied. According to the medicine provided by the invention, prescription composition is analyzed on the basis of the theory of traditional Chinese medicine, and researches are implemented in accordance with research results of physicochemical properties and pharmacological actions of ingredients in the various medicinal materials, so that a preparation method that active ingredients are reasonable and stable is offered; and the medicine provided by the invention, as being taken for 3 weeks, can relieve the depression.

Description

technical field [0001] The invention belongs to the field of traditional Chinese medicine for depression, and in particular relates to a medicine for treating depression. Background technique [0002] Depression is one of the most common mental disorders in the population. According to the World Health Organization (WHO) survey, the incidence of depression worldwide is about 3.1%. In western developed countries, the lifetime incidence of depression is between 6 and 8%. With the gradual aging of the population, the incidence of depression among people over 60 years old will be as high as 20% to 50%. It is predicted that by 2005, the incidence of depression in these countries will increase to about 8%-10%. The "2002 World Health Report" published by the World Health Organization points out that depression has become the fourth largest disease in the world, and by 2020, depression may become the second largest disease after heart disease. [0003] The treatment of depression ...

AI Technical Summary

Problems solved by technology

MAOTs have many toxic and side effects, and TCA preparations commonly used in clinical practice can be found to include nervous system, anticholinergic, and cardiovascular side effects, which limit the use of TCA

Although the safety and tolerability of new antidepressants (such as SSRI, NaSSA, SNRI, etc.) are better than TCA preparations, many patients cannot afford the cost of treatment, especially long-term treatment, because of their high cost, which makes patients Decreased medication compliance affects treatment

Images